Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
24 oct. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society...
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
03 oct. 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A...
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
06 sept. 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's...
Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
29 août 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor...
Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
11 août 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating...
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
04 août 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical...
Travere Therapeutics Reports Second Quarter 2022 Financial Results
04 août 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application...
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
01 août 2022 05h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
18 juil. 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
29 juin 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...